Next Article in Journal
A HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model
Previous Article in Journal
Combating Vaccine Hesitancy with Vaccine-Preventable Disease Familiarization: An Interview and Curriculum Intervention for College Students
Open AccessArticle

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine

1
The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK
2
Clinical BioManufacturing Facility, Churchill Hospital, University of Oxford, Oxford OX3 7JT, UK
3
Department of Nutritional Sciences, Faculty of Life Sciences & Medicine, Franklin Wilkins Building, King’s College London, London SE1 9NH, UK
*
Author to whom correspondence should be addressed.
Vaccines 2019, 7(2), 40; https://doi.org/10.3390/vaccines7020040
Received: 11 March 2019 / Revised: 30 April 2019 / Accepted: 8 May 2019 / Published: 15 May 2019
  |  
PDF [1802 KB, uploaded 13 June 2019]
  |  

Abstract

Adenovirus vectored vaccines are a highly effective strategy to induce cellular immune responses which are particularly effective against intracellular pathogens. Recombinant simian adenovirus vectors were developed to circumvent the limitations imposed by the use of human adenoviruses due to widespread seroprevalence of neutralising antibodies. We have constructed a replication deficient simian adenovirus-vectored vaccine (ChAdOx2) expressing 4 genes from the Mycobacterium avium subspecies paratuberculosis (AhpC, Gsd, p12 and mpa). Safety and T-cell immunogenicity results of the first clinical use of the ChAdOx2 vector are presented here. The trial was conducted using a ‘three-plus-three’ dose escalation study design. We demonstrate the vaccine is safe, well tolerated and immunogenic. View Full-Text
Keywords: viral vector; vaccine; T-cell; Mycobacterium avium subsp. paratuberculosis viral vector; vaccine; T-cell; Mycobacterium avium subsp. paratuberculosis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Folegatti, P.M.; Bellamy, D.; Roberts, R.; Powlson, J.; Edwards, N.J.; Mair, C.F.; Bowyer, G.; Poulton, I.; Mitton, C.H.; Green, N.; Berrie, E.; Lawrie, A.M.; Hill, A.V.; Ewer, K.J.; Hermon-Taylor, J.; Gilbert, S.C. Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. Vaccines 2019, 7, 40.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top